Search clinical trials for: Rituximab Biosimilar

Total 3565 results

AryoGen Pharmed Co.

Completed

Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

Hemophilia A or B With Inhibitor

Iran, Islamic Republic of, Turkey
University Hospital, Rouen

Not yet recruiting

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus (RITUX4)

Pemphigus | Dermatologic Disease
Byondis B.V.

Recruiting

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Lymphoma

Spain, United Kingdom, Netherlands, Italy
Epizyme, Inc.
Swedish Cancer Institute

Terminated

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Grupo Español de Linfomas y Transplante Autólogo...

Unknown

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT (MAN2)

Mantle-cell Lymphoma

Spain
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) (Z-RIC-Allo)

Non-Hodgkin Lymphoma

Spain
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

Rheumatoid Arthritis

Germany
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Sun Yat-sen University

Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular Lymphoma | Relapsed and Refractory Follicular Lymphoma

China
The Lymphoma Academic Research Organisation
CHU de Nancy

Completed

Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

DLBCL

France, Belgium
Lymphoma Study Association
Association pour le Développement de la Recherche Clinique et Informatique...

Completed

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

B Cell Lymphoma

France
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

Non-Hodgkin's Lymphoma

United States
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

France, United States, Russian Federation, Czech Republic, Australia, United Kingdom, Italy, Brazil, Israel, Poland, Ukraine, Puerto Rico
Gedeon Richter Plc.

Unknown

Comparative Pharmacokinetic Trial of RGB-03 and MabThera

Rheumatoid Arthritis
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Wolfson Medical Center

Unknown

Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia

Advanced Refractory Chronic Lymphocytic Leukemia

Israel
National Institute of Diabetes and Digestive and...
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Completed

Rituximab in New Onset Type 1 Diabetes (TN05)

Type 1 Diabetes Mellitus

United States, Canada, Italy, Australia
Pharmacyclics LLC.

Completed

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Follicular Lymphoma | B-cell Lymphoma | Non-Hodgkin's Lymphoma

United States
University of California, San Diego
Genentech, Inc.

Completed

Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)

Rheumatoid Arthritis

United States
Lymphoma Study Association

Terminated

Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

CD20-Positive Large B-Cell Lymphoma

France
University of Nebraska
Biogen

Completed

Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation

Lymphoma

United States
Jurgen Barth
Sponsor GmbH

Active, not recruiting

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas (MAINTAIN)

Non-Hodgkin's Lymphoma | Lymphocytic Lymphoma | Marginal Zone Lymphomas | Follicular Lymphomas | Immunocytomas | Mantle-Cell Lymphomas

Germany
Incyte Corporation

Withdrawn

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Marginal Zone Lymphoma (MZL) | Follicular Lymphoma ( FL)
Tokyo University
Japan Agency for Medical Research and Development; Zenyaku Kogyo Co., Ltd.

Completed

A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis (DesiReS)

Autoimmune Diseases | Collagen Diseases | Scleroderma, Systemic | Lung Fibrosis | Skin Sclerosis

Japan
Hoffmann-La Roche

Completed

A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

Rheumatoid Arthritis

Germany
Johns Hopkins University

Terminated

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

Kidney Failure

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Germany
Massachusetts General Hospital
Novartis; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center

Completed

Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
The Lymphoma Academic Research Organisation

Completed

The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas ((RAD001-R))

Non-Hodgkin's Lymphomas

France
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Germany
University Hospital Tuebingen
Hoffmann-La Roche

Completed

Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Primary Gastric Diffuse-Large B-Cell Lymphoma

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Sanofi

Recruiting

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (MAYARI)

Thrombotic Thrombocytopenic Purpura

Italy, Belgium, France, Greece, United States, Austria, Canada, Czechia, Germany, Japan, Netherlands, Spain, United Kingdom
Bioeq GmbH

Completed

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (VESPUCCI)

Plaque Psoriasis

Poland, Estonia, Ukraine, Georgia
Aprea Therapeutics

Terminated

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (R/R)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (ASSIST_FL)

Follicular Lymphoma

Russian Federation, Netherlands, Peru, United Kingdom, Romania, Brazil, Malaysia, Spain, India, Italy, Bulgaria, Poland, South Africa, Japan, Argentina, Australia, Austria, Colombia, France, Germany, Greece, Hungary, Ireland, Israel, Po... and more
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease (LowAR)

Graft vs Host Disease

Mexico
National Institute on Aging (NIA)
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Mingzhi Zhang

Unknown

Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Gruppo Italiano Studio Linfomi

Completed

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Follicular Lymphoma

Italy
Assistance Publique - Hôpitaux de Paris

Recruiting

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome (OBIRINS)

Steroid-Dependent Nephrotic Syndrome | Steroid-Sensitive Nephrotic Syndrome

France
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
Rigshospitalet, Denmark
Odense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaborators

Active, not recruiting

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (DanNORMS)

Relapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Denmark
Yang Tao

Completed

Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes

Type 1 Diabetes

China
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan

Search clinical trials for: Rituximab Biosimilar

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations